Cal.D.Forte

Valsts: Jaunzēlande

Valoda: angļu

Klimata pārmaiņas: Medsafe (Medicines Safety Authority)

Aktīvā sastāvdaļa:

Colecalciferol 1.25mg equivalent to 50,000 IU (plus 12% (0.15 mg) overage)

Pieejams no:

PSM Healthcare Ltd trading as API Consumer Brands

SNN (starptautisko nepatentēto nosaukumu):

Colecalciferol 1.25 mg (= 50,000 IU; plus 12% (0.15 mg) overage)

Deva:

1.25 mg

Zāļu forma:

Coated tablet

Kompozīcija:

Active: Colecalciferol 1.25mg equivalent to 50,000 IU (plus 12% (0.15 mg) overage) Excipient: Acacia   Ammonia solution Calcium carbonate   Castor oil Ether Gelatin Hydrated silica Lactose monohydrate Magnesium stearate Maize starch     Methylated spirits Povidone Powdered cellulose Prepared theobroma Purified talc     Purified water Shellac Sucrose   Titanium dioxide White beeswax

Vienības iepakojumā:

Bottle, glass, Amber, with PP cap, 12 tablets

Klase:

Prescription

Receptes veids:

Prescription

Ražojis:

DSM Nutritional Products France SAS

Ārstēšanas norādes:

Indicated for treatment of vitamin D deficiency associated with malabsorption in children and/or adult patients. Indicated for prevention and treatment of vitamin D deficiency states.

Produktu pārskats:

Package - Contents - Shelf Life: Bottle, glass, Amber, with PP cap - 12 tablets - 18 months from date of manufacture stored at or below 25°C

Autorizācija datums:

1996-04-01

Produkta apraksts

 
1 
DATA SHEET 

CAL.D.FORTE 
(Colecalciferol 1.25mg) 

PRESENTATION 
Cal.D.Forte Tablets contain 1.25mg of colecalciferol. 
White, sugar-coated, 8mm, biconvex tablet_. _

USES 
ACTIONS:   
Colecalciferol is a vitamin D
compound which possesses the property of preventing 
or treating rickets.   

Vitamin D is essential for
promoting absorption and utilisation of calcium and 
phosphate and for normal
calcification of bone.  Along with parathyroid hormone and 
calcitonin, it regulates serum calcium concentrations
by increasing serum calcium 
and phosphate concentrations as needed.  Vitamin D stimulates
calcium and 
phosphate absorption from the small intestine and mobilises calcium from bone. 

Colecalciferol is transferred to the liver where it is
converted to calcifediol (25-
hydroxycolecalciferol), which is then transferred to the kidneys
and converted to 
calcitriol
(1,25-dihyroxycolecalciferol, thought to be the most active form)
and 24,25-
dihydroxycolecalciferol (physiologic role not determined).  

Calcitriol appears to act by binding to a specific receptor
in the cytoplasm of the 
intestinal
mucosa and subsequently being incorporated into the nucleus, probably 
leading to formation of the calcium-binding protein which results in increased 
absorption of calcium from the intestine.  Also, calcitriol
may regulate the transfer of 
calcium ion from bone and stimulate reabsorption of calcium in the distal
renal 
tubule, thereby effecting calcium homeostasis
in the extracellular fluid. 

ONSET OF ACTION 
– Hypercalcaemic: 12 to 24 hours; therapeutic
effect may take 10 to 
14 days. 

DURATION OF ACTION 
– Following oral
administration: up to 6 months; repeated doses 
have a cumulative action. 

PHARMACOKINETICS:   
Vitamin D substances are well absorbed from the gastrointestinal
tra